ES
38
2
CCL
33
-6
PLD
38
-7
SIG
70
-2
SYK
55
-5
MA
51
-4
GRMN
80
16
GIS
58
-3
ETN
78
-2
PGR
74
4
MTB
52
3
ACN
29
-2
KHC
36
-14
REGN
62
3
SWKS
38
-15
NKE
36
-3
TMO
63
3
KIM
48
-6
AEP
42
3
AON
19
2
ES
38
2
CCL
33
-6
PLD
38
-7
SIG
70
-2
SYK
55
-5
MA
51
-4
GRMN
80
16
GIS
58
-3
ETN
78
-2
PGR
74
4
MTB
52
3
ACN
29
-2
KHC
36
-14
REGN
62
3
SWKS
38
-15
NKE
36
-3
TMO
63
3
KIM
48
-6
AEP
42
3
AON
19
2
Financhill
Back

Heron Therapeutics 10K Form

Sell
30

HRTX
Heron Therapeutics

Last Price:
2.35
Seasonality Move:
8.75%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive HRTX News And Ratings

See the #1 stock for the next 7 days that we like better than HRTX

HRTX Financial Statistics

Sales & Book Value

Annual Sales: $127.04M
Cash Flow: $2.21M
Price / Cash Flow: 0
Annual Sales: $-0.23
Price / Book: 0

Profitability

EPS (TTM): -0.84000
Net Income (TTM): $-110.56M
Gross Margin: $61.94M
Return on Equity: 0%
Return on Assets: -49.15%

Heron Therapeutics Earnings Forecast

Key Heron Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 37 years for HRTX is 48.75%.
  • The Selling, General & Administrative Expenses for HRTX have been equal to 91.82% of Gross Profit Margin.
  • The Research & Development expenses have been 44.00% of Revenue.
  • The Interest Expense is -3.50% of Operating Income.
  • The Net Earning history of HRTX is -87.02% of Total Revenues.
  • Per Share Earnings over the last 37 years have been positive in 20 years.

Heron Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: HRTX
CUSIP: 427746
Website: herontx.com

Debt

Debt-to-Equity Ratio: -5.11
Current Ratio: 2.37
Quick Ratio: 1.76

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

HRTX Technical Analysis vs Fundamental Analysis

Sell
30
Heron Therapeutics (HRTX) is a Sell

Is Heron Therapeutics a Buy or a Sell?